Daptomycin disrupts membrane potential in growing Staphylococcus aureus. - Wikidata - wikimedia - TriplyDB

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

http://www.wikidata.org/entity/Q36756893

about

Characterization of the physiological requirements for the bactericidal effects of a monoclonal antibody to OspB of Borrelia burgdorferi by confocal microscopy Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells Combinations of β-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant Staphylococcus aureus A well-defined amphipathic conformation for the calcium-free cyclic lipopeptide antibiotic, daptomycin, in aqueous solution.Systemic antibacterial activity of novel synthetic cyclic peptides.Management of community-associated methicillin-resistant Staphylococcus aureus infections in children.Development of daptomycin for gram-positive infections.Multiple mechanisms of action for inhibitors of histidine protein kinases from bacterial two-component systems.In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection.Resistance studies with daptomycin Comparative mechanistic studies of brilacidin, daptomycin, and the antimicrobial peptide LL16.Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.Natural products to drugs: daptomycin and related lipopeptide antibiotics.Therapies in development for community-acquired pneumonia.Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001 Differential increased survival of staphylococci and limited ultrastructural changes in the core of infected fibrin clots after daptomycin administration.Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus.A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections.Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons Cutaneous infections and infestations: new therapies Activity of daptomycin against recent North American isolates of Streptococcus pneumoniae Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.In vitro activity of vancomycin against the spirochete Borrelia burgdorferi.Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.Intrinsic and acquired resistance mechanisms in enterococcus.Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization.In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapy.Use of multivariate analysis to compare antimicrobial agents on the basis of in vitro activity data Role of the LytSR two-component regulatory system in adaptation to cationic antimicrobial peptides in Staphylococcus aureus A current perspective on daptomycin for the clinical microbiologist.Causal role of single nucleotide polymorphisms within the mprF gene of Staphylococcus aureus in daptomycin resistance Pre-clinical experience with daptomycin.Daptomycin inhibits cell envelope synthesis by interfering with fluid membrane microdomains.Cardiolipin prevents membrane translocation and permeabilization by daptomycin.Complicated skin and soft tissue infections: literature review of evidence for and experience with daptomycin.

P2860

Q24675314-8D991B89-ADBB-49C4-8323-725B71EE0191 Q24682375-8E68B70B-2229-4FD3-A4A2-E3310DF2333C Q28543476-22BFC765-5619-4AA1-871F-1F56AA0554B3 Q30986704-0340377B-256F-408B-A58F-866934BE83F6 Q33220464-18740293-14DC-432A-B1E0-E854F9B83DF0 Q33264579-E92D5BCE-B3F5-4651-A667-3A81244C261E Q33920377-DE19DE09-F337-4853-9E40-4E68FBAA0473 Q33977169-76EB0AA7-EEF8-482C-87C1-6F04B1EAEEF2 Q33979251-1CD615CE-4C2F-4463-B164-012BA57CC6F7 Q33981666-5FF1565D-7943-4D8F-AA5D-DEF65C21EF7F Q33982318-AFA59CCE-1C10-4050-9CA7-7A77EDACDDAF Q34057457-5C6ED676-2DD6-45DE-9DBE-649DC59BC207 Q34230034-272872A5-BAD6-406D-835E-23C4608CEE49 Q34330270-8FE477CC-A791-4023-9157-A96D6C863555 Q34470713-5269411A-F18A-4E44-A14A-DCF78D8CED26 Q34581508-724E1F9A-A8CE-498B-BBAB-0DE44291A44C Q34648042-A4CD7004-9B22-4802-B130-6CB404456984 Q34939045-C8CB0102-D168-4D64-834F-94EC6C028C66 Q35121985-65485E42-53C6-462F-B68E-E06E219FC387 Q35166213-B10E6E51-E7D7-4458-A317-E2FBB02CAD27 Q35166807-C5CA13FD-26C3-4FA9-A3C5-A5E400A07E79 Q35256159-F9EEB983-1F23-40F8-BBCE-F38C87EB34E6 Q35628618-317DDE22-2F76-4C51-BEAC-732E390D1932 Q35685343-9DC4C187-728E-4671-A258-53B6AE112CC6 Q35771368-5BD15350-7A49-4939-8A00-42D8A4D84D8F Q35815090-CD2E249C-8688-4606-963E-C3900BAF3445 Q35836523-5C2E87A6-7F86-434B-A93A-B65E2500CEDF Q35871928-041DCBFB-8291-4F79-8573-013B1A36E814 Q36362547-097BFA4F-739F-4960-ADFD-6414ECCBFB60 Q36482900-1180B3F7-D1E4-4EBB-AD81-F476234E7DCB Q36492244-A421F4E4-0E7F-44C9-AD06-9689A12A28FC Q36738730-409EA799-C7FC-40A5-96E2-7CD45800D7DD Q36751113-F5DC34F1-DE22-4A5B-A326-2C1B05F42C7D Q37036548-CADD2A35-DE66-40DA-BACE-AA33EF6E7781 Q37263289-43A240EB-6F9E-4912-9540-9467133B607F Q37263514-BE1D4B73-491E-40A1-ABC4-1A7EB6E99D4E Q37284356-5727F58F-A52C-4D35-BB1A-74422E15A315 Q37417749-E3558B71-FA5C-4CCA-BC55-5013982E470F Q37727568-C54EDB24-C5E7-414F-B800-B0C2E97626D5 Q37900838-D3D8EBD0-3118-45D5-8C32-76E2D5A85B16

P2860

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

http://www.wikidata.org/entity/Q36756893

description

1991 nî lūn-bûn

@nan

1991年の論文

@ja

1991年論文

@yue

1991年論文

@zh-hant

1991年論文

@zh-hk

1991年論文

@zh-mo

1991年論文

@zh-tw

1991年论文

@wuu

1991年论文

@zh

1991年论文

@zh-cn

name

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@ast

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@en

type

label

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@ast

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@en

prefLabel

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@ast

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@en

P1433

Q36756893-B7D804D1-D27E-43E5-902B-020B05614E17

P1476

Q36756893-CACCB29A-A98C-46F3-98A1-02298FBD5579

P2093

Q36756893-063BBAA5-8198-467B-BBF8-E8AE6B5D6D6C

Q36756893-CAB74DF2-C05C-4F1A-BD1F-453C54A06873

Q36756893-EC3C9A4A-1895-4B93-862A-9576202EF66D

P2860

Q36756893-1625F4BD-7FA0-4705-8F61-DED3448A945E

Q36756893-48393406-7B75-4084-B833-F474F54E5895

Q36756893-85F2282C-FE7D-42EF-B25A-336491A2FCE7

Q36756893-87A0E246-9242-46AF-AF1B-07D6E1FA0C26

Q36756893-88CCD92D-18EB-4C2B-8294-B14499CE0E19

Q36756893-9A60385F-B668-4B2D-927F-D6E549EC442F

Q36756893-A872CDFC-57C3-4F7E-B800-E5BF35CAE495

Q36756893-A89A0E84-6517-44EA-82B8-A30EAE76744E

Q36756893-B9ABDB03-6B86-47D1-920A-F8C1C88D8E68

Q36756893-D3460DCC-C271-4317-BACC-1158C35734CA

P304

Q36756893-18442FB2-840B-4E2C-AAEB-E22914ED9D9B

P31

Q36756893-5D344D6D-3B51-4697-8E82-627536600F7D

P356

Q36756893-C5B4708F-BE26-4F83-B77C-226CEE211035

P407

Q36756893-6136E050-B972-4C91-A1A3-77359DBC8163

P433

Q36756893-5A555001-6BC0-4A6D-8ACB-7D7468D222D8

P478

Q36756893-0EAD79B3-1276-46C0-94C5-D6AB3FC9979A

P577

Q36756893-13368D57-D52B-40A7-A796-D6B2EF595793

P698

Q36756893-354C6231-3B81-4CCD-A449-ED2CD8742493

P932

Q36756893-A5A70D08-4E91-40C3-B9BE-33C40734C845

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Daptomycin disrupts membrane potential in growing Staphylococcus aureus.

@en

P2093

Alborn WE Jr

http://www.w3.org/2001/XMLSchema#string

Allen NE

http://www.w3.org/2001/XMLSchema#string

Preston DA

http://www.w3.org/2001/XMLSchema#string

P2860

In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic

Quantitative association between electrical potential across the cytoplasmic membrane and early gentamicin uptake and killing in Staphylococcus aureus

Membrane potential and gentamicin uptake in Staphylococcus aureus

Bacterial uptake of aminoglycoside antibiotics.

The use of flow dialysis for determinations of deltapH and active transport.

Lipoteichoic acid as a new target for activity of antibiotics: mode of action of daptomycin (LY146032)

Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032

In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibiotic.

Mode of action of the peptide antibiotic nisin and influence on the membrane potential of whole cells and on cytoplasmic and artificial membrane vesicles.

Transport of protons across membranes by weak acids.

P304

2282-2287

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.35.11.2282

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

35

http://www.w3.org/2001/XMLSchema#string

P577

1991-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

1666494

http://www.w3.org/2001/XMLSchema#string

P932

245372

http://www.w3.org/2001/XMLSchema#string